Search
Displaying 181–190 of 896 results for “vision connection”
-
Presentation Summaries from the 10th Annual Retinal Therapy Innovation Summit
Research NewsIn its tenth year, the Innovation Summit featured 28 presentations from industry professionals worldwide and more than 400 attendees.
-
VISIONS 2024, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
Quarterly vision webinars providing key information impacting our community.
-
Forty-Four High-Impact Retinal-Research Efforts Highlighted at FFB-Casey Innovation Summit
Research NewsIn its fourth year, the meeting is becoming the world’s most comprehensive overview of the promising research underway for emerging IRD treatments.
-
Funded Grants and Awards for Fiscal Year 2019 (July 1, 2018-June 30, 2019)
-
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
In the PressAN EMERGING, vision-restoring gene therapy for a devastating retinal disease is poised for Food and Drug Administration (FDA) approval. If it gets the regulatory nod, it will be the first gene therapy to receive FDA approval for the eye or an inherited condition.
-
The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for blinding retinal diseases, is hosts webinars to inform eye care professionals about the many opportunities to greatly enhance the quality of life, and provide hope, for their retinal disease patients.
-
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
Foundation NewsThe Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
In the Press
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.
-
Retinitis Pigmentosa Research Advances
Research NewsRecent developments in research on retinitis pigmentosa.
